At4g39280 Antibody

What is the At4g39280 gene and what protein does it encode?

At4g39280 is an Arabidopsis thaliana gene encoding a phenylalanyl-tRNA synthetase (PheRS) that is primarily localized in the cytosol. According to genomic analysis, this gene is expressed in Arabidopsis, as evidenced by positive EST (expressed sequence tag) and full-length mRNA detection . This enzyme belongs to the aminoacyl-tRNA synthetase family, which are essential enzymes that catalyze the esterification of specific amino acids to their cognate tRNAs during protein synthesis. The At4g39280-encoded PheRS specifically handles the charging of tRNA with phenylalanine in the cytosolic compartment of plant cells .

What are the best sample preparation methods for At4g39280 antibody applications?

For optimal results with At4g39280 antibodies, sample preparation should begin with efficient protein extraction from plant tissues. Fresh tissue should be flash-frozen in liquid nitrogen and ground to a fine powder. Extraction should be performed using a buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, and protease inhibitor cocktail. For subcellular fractionation to confirm cytosolic localization, differential centrifugation techniques should be employed.

The protein extract should be clarified by centrifugation at 12,000×g for 15 minutes at 4°C. For immunoprecipitation applications, pre-clearing the lysate with protein A/G beads is recommended to reduce non-specific binding. Western blot applications typically require 20-50 μg of total protein per lane, separated on 10-12% SDS-PAGE gels, followed by transfer to PVDF membranes for optimal antibody binding .

How can I validate the specificity of an At4g39280 antibody?

Validation of At4g39280 antibody specificity requires multiple complementary approaches. Primary validation should include Western blot analysis using both recombinant At4g39280 protein and wild-type Arabidopsis protein extracts, with knockout/knockdown plants serving as negative controls. The antibody should detect a single band at the expected molecular weight (~50-70 kDa, depending on the specific isoform).

Secondary validation should employ immunoprecipitation followed by mass spectrometry to confirm the identity of the pulled-down protein. Cross-reactivity testing against related tRNA synthetases, particularly the chloroplastic PheRS (At3g58140) and mitochondrial PheRS (At1g72550), is essential to ensure specificity . Epitope mapping can provide additional confirmation that the antibody recognizes the intended target sequence. For definitive validation, performing immunoblotting with Arabidopsis mutants where At4g39280 expression is disrupted will demonstrate antibody specificity through absence of the target band.

What are the common applications for At4g39280 antibodies in plant research?

At4g39280 antibodies serve multiple applications in plant molecular biology research. Western blotting represents the most common application, enabling detection and quantification of PheRS expression levels across different plant tissues, developmental stages, or stress conditions.

Immunoprecipitation applications allow researchers to study protein-protein interactions involving At4g39280-encoded PheRS, potentially revealing regulatory complexes that govern translation processes. Immunohistochemistry and immunofluorescence applications can map the spatial distribution of the protein within plant tissues and cells, confirming its predominantly cytosolic localization .

For functional studies, At4g39280 antibodies can be used in activity inhibition assays to assess the impact of PheRS inhibition on protein synthesis. Finally, chromatin immunoprecipitation (ChIP) may be applicable if the protein is found to have moonlighting functions related to gene regulation, a phenomenon observed with some aminoacyl-tRNA synthetases in other organisms.

How can I distinguish between antibodies targeting the cytosolic At4g39280 and those targeting organellar phenylalanyl-tRNA synthetases?

Distinguishing between antibodies targeting different cellular compartment-specific PheRS isoforms requires careful epitope selection and validation strategies. The cytosolic At4g39280-encoded PheRS has distinct sequence regions compared to its chloroplastic (At3g58140) and mitochondrial (At1g72550) counterparts . When generating antibodies, targeting these unique regions is essential.

For validation, subcellular fractionation followed by Western blotting should show enrichment of At4g39280 signal in cytosolic fractions but not in organellar fractions. Conversely, antibodies against organellar PheRS should show enrichment in the respective organelle fractions. Immunofluorescence microscopy with co-staining using organelle-specific markers can provide visual confirmation of isoform-specific localization.

Pre-adsorption tests can further confirm specificity: pre-incubating the antibody with recombinant At4g39280 protein should abolish cytosolic staining while leaving organellar staining intact when using antibodies against organellar PheRS. Additionally, performing Western blots on protein extracts from mutant plants with reduced expression of specific PheRS isoforms can demonstrate the specificity of each antibody.

What are the optimal conditions for detecting post-translational modifications of At4g39280-encoded PheRS using specific antibodies?

Detecting post-translational modifications (PTMs) of At4g39280-encoded PheRS requires specialized antibodies and optimized protocols. For phosphorylation analysis, samples should be prepared with phosphatase inhibitors (10 mM sodium fluoride, 1 mM sodium orthovanadate, and 10 mM β-glycerophosphate) in the extraction buffer. Immunoprecipitation with the At4g39280 antibody followed by immunoblotting with phospho-specific antibodies (anti-phosphoserine, anti-phosphothreonine, and anti-phosphotyrosine) can reveal phosphorylation status.

For other PTMs such as acetylation, ubiquitination, or SUMOylation, similar approaches can be employed using modification-specific antibodies after immunoprecipitation with At4g39280 antibody. Alternatively, mass spectrometry analysis of immunoprecipitated At4g39280 can provide comprehensive PTM profiling.

When studying PTM dynamics, researchers should consider comparing different stress conditions, developmental stages, or treatment with hormones that might regulate PheRS activity through post-translational mechanisms. Two-dimensional gel electrophoresis before Western blotting can help resolve different modified forms of the protein based on both molecular weight and isoelectric point.

How can At4g39280 antibodies be used to investigate protein-protein interactions in the aminoacyl-tRNA synthetase complex?

Investigating protein-protein interactions involving At4g39280-encoded PheRS requires sophisticated immunological approaches. Co-immunoprecipitation (co-IP) represents the primary method: using At4g39280 antibody to pull down the protein complex followed by mass spectrometry or Western blotting with antibodies against suspected interaction partners.

For more dynamic studies, proximity ligation assays (PLA) can visualize interactions in situ by combining At4g39280 antibody with antibodies against putative interaction partners. This technique produces fluorescent signals only when proteins are in close proximity (<40 nm), suggesting physical interaction.

Bimolecular fluorescence complementation (BiFC) can complement antibody-based approaches by confirming interactions detected through co-IP. While not directly using antibodies, this validation step strengthens findings from antibody-based interaction studies. For mapping interaction domains, truncated versions of At4g39280 can be expressed and immunoprecipitated to determine which regions are essential for specific protein-protein interactions.

To investigate whether the cytosolic PheRS forms part of a multi-aminoacyl-tRNA synthetase complex (similar to those in mammalian systems), sequential co-IP can be performed: first immunoprecipitating with At4g39280 antibody, then using antibodies against other tRNA synthetases on the eluted material.

What techniques can overcome cross-reactivity challenges when using At4g39280 antibodies in complex plant extracts?

Overcoming cross-reactivity issues with At4g39280 antibodies requires several technical strategies. Pre-adsorption of antibodies with recombinant proteins representing potential cross-reactive targets (particularly other PheRS isoforms) can significantly enhance specificity. This involves incubating the antibody with excess recombinant protein before use in the actual experiment.

For Western blotting applications, gradient gels (4-20%) can provide better separation of similarly sized proteins, helping to resolve At4g39280-encoded PheRS from potential cross-reactive proteins. High-stringency washing conditions (0.1% SDS in wash buffer) can reduce non-specific binding.

Epitope-specific antibodies targeting unique regions of At4g39280 should be preferred over those targeting conserved domains shared with other tRNA synthetases. Competitive ELISA can quantitatively assess cross-reactivity by measuring antibody binding in the presence of increasing concentrations of potential cross-reactive proteins.

For particularly challenging applications, subtraction analysis can be employed by comparing signal patterns between wild-type and At4g39280 knockdown/knockout lines, where signals present in both samples would indicate cross-reactivity. Finally, antibody purification by affinity chromatography using immobilized At4g39280-specific peptides can enrich for antibodies with the highest specificity.

How should I design experiments to study At4g39280 expression changes under different stress conditions?

Experimental design for studying At4g39280 expression under stress conditions should incorporate multiple biological and technical replicates (minimum n=3) and appropriate controls. Time-course experiments are essential, with samples collected at 0, 1, 3, 6, 12, 24, and 48 hours after stress application to capture both early and late responses.

Sample preparation should maintain consistent harvesting times to control for circadian regulation effects. Protein extraction protocols must include protease inhibitors and rapid processing at 4°C to prevent degradation. For Western blot analysis, equal protein loading should be verified using constitutively expressed proteins such as actin or GAPDH as loading controls .

Statistical analysis should employ ANOVA with post-hoc tests for time-course data, or t-tests for simple comparisons. Quantification of Western blot signals should use digital image analysis software, normalizing At4g39280 signals to loading control signals. To comprehensively characterize expression patterns, combining protein-level analysis (using antibodies) with transcript-level analysis (RT-qPCR) will provide insights into transcriptional and post-transcriptional regulation mechanisms.

What control experiments are essential when using At4g39280 antibodies for immunolocalization studies?

Essential controls for immunolocalization studies with At4g39280 antibodies include multiple technical and biological controls. Primary antibody specificity controls should include: (1) omission of primary antibody, (2) use of pre-immune serum, (3) pre-adsorption of antibody with recombinant At4g39280 protein, and (4) testing in knockout/knockdown plant lines.

Subcellular localization controls should include co-staining with established markers for different cellular compartments (e.g., DAPI for nucleus, mitochondrial and chloroplast-specific proteins). When confirming cytosolic localization of At4g39280-encoded PheRS, markers such as cytosolic GAPDH should co-localize, while organellar markers should show distinct patterns .

Technical controls should address autofluorescence (sample processing without any antibodies) and cross-reactivity of secondary antibodies (applying only secondary antibody). When comparing localization patterns between different conditions or genotypes, standardized image acquisition parameters and quantitative image analysis should be employed to ensure objective interpretation of results.

How can I quantitatively assess At4g39280 protein expression levels using antibody-based techniques?

Quantitative assessment of At4g39280 protein expression requires rigorous methodological approaches. Western blotting with standardized protocols offers semi-quantitative analysis when combined with digital densitometry. Standard curves using recombinant At4g39280 protein at known concentrations should be included on each gel to enable absolute quantification.

For higher throughput, ELISA can be developed using At4g39280 antibodies as capture antibodies and biotin-conjugated At4g39280 antibodies (recognizing a different epitope) as detection antibodies in a sandwich format. Standard curves with recombinant protein enable absolute quantification with higher sensitivity than Western blotting.

For single-cell resolution of expression levels, flow cytometry can be applied to protoplasts using fluorescently-labeled At4g39280 antibodies. This technique allows statistical analysis of expression across cell populations. Alternatively, quantitative immunohistochemistry using standardized staining protocols and image analysis software can provide spatial information on expression levels across different tissues or cell types.

When comparing samples, normalization to housekeeping proteins is essential, and multiple reference proteins should be used to ensure robust normalization. Statistical analysis should include assessment of technical variation (replicate measurements of the same sample) and biological variation (measurements across different plants or treatments).

What are the most common causes of false positives/negatives in At4g39280 antibody applications, and how can they be addressed?

False positives in At4g39280 antibody applications commonly arise from cross-reactivity with related tRNA synthetases, particularly the other PheRS isoforms (At3g58140 and At1g72550) . This can be addressed by using highly specific antibodies targeting unique epitopes of At4g39280, performing validation with knockout/knockdown lines, and including competition controls with recombinant proteins.

Non-specific binding to abundant proteins may occur, especially in immunoprecipitation experiments. Increasing stringency of wash buffers (0.1-0.5% SDS or 500 mM NaCl) and pre-clearing lysates with protein A/G beads can minimize this issue. For Western blotting, longer blocking times (2 hours at room temperature) with 5% BSA instead of milk can reduce background.

False negatives commonly result from protein degradation during sample preparation. Including multiple protease inhibitors and processing samples rapidly at 4°C is essential. Epitope masking due to protein folding or post-translational modifications can prevent antibody binding; using denaturing conditions for Western blots and testing multiple antibodies targeting different epitopes can overcome this limitation.

Insufficient sensitivity may occur with low-abundance targets. Signal amplification methods (e.g., tyramide signal amplification for immunohistochemistry) or more sensitive detection methods (chemiluminescence with longer exposure times, or fluorescent secondary antibodies with digitial imaging) can enhance detection of low-abundance targets.

How should I interpret contradictory results between antibody-based detection and transcript-level analysis of At4g39280?

Contradictory results between protein and transcript levels for At4g39280 should be interpreted through the lens of post-transcriptional regulation mechanisms. Discrepancies where protein levels don't match mRNA levels could indicate:

• Post-transcriptional regulation through microRNAs or RNA-binding proteins affecting translation efficiency

• Post-translational regulation affecting protein stability (ubiquitination and proteasomal degradation)

• Technical limitations in either protein or transcript detection methods

To resolve these contradictions, time-course experiments can reveal temporal relationships between transcript and protein levels, potentially showing delays between mRNA increase and protein accumulation. Pulse-chase experiments using protein synthesis inhibitors can assess protein stability under different conditions.

Additionally, polysome profiling can determine if the transcript is actively translated, and proteasome inhibitors can reveal if protein turnover mechanisms are responsible for discrepancies. When reporting contradictory results, both datasets should be presented with clear descriptions of methodologies and limitations, avoiding overinterpretation of either dataset in isolation.

How can I differentiate between specific antibody binding and background signal in immunofluorescence studies of At4g39280?

Differentiating specific binding from background in immunofluorescence requires systematic controls and quantitative approaches. Signal from specific binding typically shows consistent subcellular localization patterns aligned with known protein function (cytosolic for At4g39280-encoded PheRS) , whereas background signal often appears more diffuse or follows non-biological patterns.

Quantitative signal-to-noise ratio analysis can be performed by measuring fluorescence intensity in regions expected to contain the protein versus regions where the protein should be absent. A ratio significantly above 1.0 indicates specific binding. Signal extinction tests provide definitive evidence: pre-incubation of the antibody with excess target antigen should abolish specific signals while leaving background signal intact.

Comparative analysis between wild-type plants and plants with reduced At4g39280 expression should show corresponding reduction in antibody signal intensity if binding is specific. For multi-channel imaging, co-localization analysis with known markers can distinguish specific signal (which should co-localize with appropriate compartment markers) from background (which typically shows random distribution relative to markers).

Finally, consistent reproducibility across multiple samples, antibody lots, and experimental conditions strongly supports signal specificity, whereas background tends to be more variable.

How does the performance of polyclonal versus monoclonal antibodies differ for At4g39280 detection applications?

For applications requiring absolute specificity (distinguishing between highly similar PheRS isoforms), monoclonals are preferred. For maximum sensitivity in detecting low abundance variants or modified forms, polyclonals offer advantages. A complementary approach using both antibody types provides the most comprehensive analysis: polyclonals for initial detection and monoclonals for confirmation of specificity.

For quantitative applications like ELISA, monoclonals typically provide better standardization for absolute quantification, while polyclonals may offer broader detection of modified forms in complex samples.

How can I integrate antibody-based detection with mass spectrometry for comprehensive analysis of At4g39280 protein?

Integrating antibody-based methods with mass spectrometry creates a powerful approach for At4g39280 analysis. Immunoprecipitation using At4g39280 antibodies followed by mass spectrometry (IP-MS) enables identification of protein interaction partners and post-translational modifications. For maximum coverage, gentle elution conditions should preserve protein-protein interactions, and alkylation of cysteine residues should be performed to improve peptide identification.

Selected reaction monitoring (SRM) or parallel reaction monitoring (PRM) mass spectrometry can provide absolute quantification of specific At4g39280 peptides, offering orthogonal validation of antibody-based quantification. For comprehensive PTM mapping, enrichment of phosphopeptides, glycopeptides, or other modified peptides after immunoprecipitation enhances detection of low-abundance modified forms.

Cross-linking mass spectrometry (XL-MS) after antibody-based purification can reveal spatial relationships between At4g39280 and its interaction partners. For validating antibody specificity, immunoprecipitated proteins can be analyzed by MS to confirm target identity and assess potential cross-reactivity.

When reporting integrated results, clear documentation of all experimental parameters (antibody concentrations, IP conditions, MS acquisition parameters) enables reproducibility. Bioinformatic integration of antibody-based quantification with MS-based identification strengthens confidence in findings through orthogonal validation.

What considerations are important when comparing At4g39280 antibody results across different plant species?

Cross-species applications of At4g39280 antibodies require careful sequence analysis and validation steps. Sequence alignment of At4g39280 orthologs across target species should be performed to predict cross-reactivity, focusing particularly on the antibody epitope regions. Conservation analysis can identify species where the antibody is likely to work versus those requiring new antibody development.

Validation in each new species is essential through Western blotting, demonstrating appropriate molecular weight and expression pattern. Positive and negative controls should include Arabidopsis extracts (positive control) and extracts from species with low sequence conservation at the epitope (negative control).

For phylogenetically distant species, antibody concentration may need optimization, typically requiring higher concentrations than used for Arabidopsis. When reporting cross-species results, sequence similarity scores between the species' orthologs should be included, particularly for the epitope regions.

When differences in antibody reactivity are observed between species, distinguishing between true biological differences versus technical limitations requires complementary approaches such as RNA-seq to confirm expression patterns at the transcript level. Finally, species-specific protein extraction protocols may be necessary to account for differences in cell wall composition, secondary metabolites, or proteases that could affect protein recovery and antibody binding.